Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
September 11 2024 - 7:00AM
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company
interrogating extrachromosomal DNA (ecDNA) biology to deliver
transformative therapies to patients with previously intractable
oncogene amplified cancers, today announced that Zachary Hornby,
President and Chief Executive Officer, and Jami Rubin, Chief
Financial Officer, will participate in the 2024 Cantor Global
Healthcare Conference.
A fireside chat session is scheduled for
Wednesday, September 18, 2024, in New York, NY, at 10:20 a.m. ET. A
live and archived webcast of the session will be accessible under
“Events & Presentations” in the Investors section of Boundless
Bio’s website.
About Boundless Bio
Boundless Bio is a clinical-stage oncology
company dedicated to unlocking a new paradigm in cancer
therapeutics to address the significant unmet need of patients with
oncogene amplified tumors by targeting extrachromosomal DNA
(ecDNA), a root cause of oncogene amplification observed in more
than 14% of cancer patients. Boundless Bio is developing the first
ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor
of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2
clinical trial in patients with oncogene amplified cancers.
Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of
ribonucleotide reductase (RNR) being evaluated in a Phase 1/2
clinical trial in cancer patients with resistance gene
amplifications. Leveraging its Spyglass platform, Boundless Bio has
additional programs advancing through preclinical development and
discovery. Boundless Bio is headquartered in San Diego, CA.
For more information,
visit www.boundlessbio.com.
Follow us on LinkedIn and X.
Contacts: Ben Flaum, Boundless
Biobflaum@boundlessbio.com
InvestorsTHRUST Strategic CommunicationsRenee
Leckrenee@thrustsc.com
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Sep 2023 to Sep 2024